KR890002155A - 저혈당제로서의 푸린의 피페라지닐 유도체 및 이의 제조방법 - Google Patents
저혈당제로서의 푸린의 피페라지닐 유도체 및 이의 제조방법 Download PDFInfo
- Publication number
- KR890002155A KR890002155A KR1019880009044A KR880009044A KR890002155A KR 890002155 A KR890002155 A KR 890002155A KR 1019880009044 A KR1019880009044 A KR 1019880009044A KR 880009044 A KR880009044 A KR 880009044A KR 890002155 A KR890002155 A KR 890002155A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- lower alkyl
- och
- methyl
- hydrogen
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 229940126904 hypoglycaemic agent Drugs 0.000 title 1
- 125000004193 piperazinyl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 28
- 208000008589 Obesity Diseases 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims abstract 3
- 235000020824 obesity Nutrition 0.000 claims abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract 3
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 229910052757 nitrogen Inorganic materials 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- -1 ethyl methoxy, ethoxy, amino, methylamino, dimethylamino, pyrrolidino Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000003302 alkenyloxy group Chemical group 0.000 claims 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- FFNVVVLETZYYJN-UHFFFAOYSA-N 6-piperazin-1-yl-7h-purine Chemical compound C1CNCCN1C1=NC=NC2=C1NC=N2 FFNVVVLETZYYJN-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
Abstract
내용없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (25)
- 하기 일반식의 화합물 및 이의 약제학적으로 허용되는 염.상기식에서, X 및 Y는 하기 의미를 가지며 ;R1및 R3는 독립적으로 수소, 저급알킬, 사이클로 저급알킬, 저급알케닐, 저급알콕시저급알킬, 저급알키닐, 또는 페닐저급알킬 또는 치환체가 1 내지 3의 할로겐, 저급알킬티오, 저급알킬설피닐, 저급알킬설포닐, 저급알킬 아미노 또는 디저급알킬아미노 이거나 산소 또는 치환체가 헤테로원자로서의 질소, 산소 또는 황을 갖는 5-또는 6-원 헤테로 방향족 환계중의 하나인 치환된 저급알킬이며, m 및 n은 0 또는 1이고, 단 m이 0이면 n은 1이며, 단 m이 1이면 n은 0이며, R2및 R4는 독립적으로 수소, 저급알킬, 사이클로 저급알킬, 저급알콕시, 저급알킬티오, 저급알킬설피닐, 저급알킬설포닐, 저급알케닐, 저급알케닐옥시, 저급알키닐, 모노, 디 또는 트리할로저급알킬, 페닐 또는 치환체가 1 내지 3의 할로 또는 저급알킬, 페닐저급알킬, 아미노, 저급알킬 아미노 또는 디알킬아미노 이고 여기에서 알킬 그룹은 선형, 측쇄이거나 헤테로원자로서 산소 또는 질소를 임의로 함유하는 5-또는 6-원환에 결합될 수 있는 치환된 페닐이다.
- 제1항에 있어서, R1이 수소, 저급알킬, 또는 저급알케닐이고, R2가 저급알킬, 저급알콕시, 아미노, 저급알킬아미노, 디저급알킬아미노 또는 피롤리디노이며, R3은 각기 독립적으로 수소, 저급알킬, 저급알콕시저급알킬, 또는 할로겐화된 저급알킬인 화합물.
- 제2항에 있어서, R1이 수소, 메틸, 에틸 또는 2-프로페닐이고, R2가 메틸, 에틸 메톡시, 에톡시, 아미노, 메틸아미노, 디메틸아미노, 피롤리디노 또는 에틸아미노이며, R3은 각각 독립적으로 수소, 메틸, 에틸, n-프로필, i-프로필, 메톡시메틸, 메톡시에틸, 또는 플루오로에틸이고, R4은 각각 독립적으로 수소, 메틸, 메틸아미노 또는 디메틸아미노인 화합물.
- 제1항에 있어서, 하기 일반식의 화합물.상기식에서, Y는 S 또는 N-R3이고, 상응하는 X는 N 또는 C-R3이며, R1, R2, R3및 R4는 제1항에서 정의한 바와 같다.
- 제3항에 있어서, X 및 Y가 독립적으로 N 및 N-R3인 화합물.
- 제5항에 있어서, X가 N이고 Y가 N-R3인 화합물.
- 제6항에 있어서, R3가 할로겐화된 측쇄 저급 알킬인 화합물.
- 제7항에 있어서, R3가 할로겐화된 이소프로필 그룹인 화합물.
- 제8항에 있어서, R3가 불소화된 이소프로필 그룹인 화합물.
- 제9항에 있어서, R3가 1,3-디플루오로 이소프로필인 화합물.
- 제5항에 있어서, R1이 수소 또는 메틸이고, R2및 R4가 독립적으로 수소, 메틸, 메톡시, 에톡시 또는 디메틸아미노인 화합물.
- 제1항에 있어서, X=N, Y=N-CH3, R4=H, R2=CH2CH3및 R4=H인 화합물.
- 제1항에 있어서, X=N, Y=N-CH2CH2CH3, R1=H, R2-OMe 및 R4=H인 화합물.
- 제1항에 있어서, X=N, Y=N-CH2OCH3, R1=H, R2=OCH2CH3및 R4=H인 화합물.
- 제1항에 있어서, X=N, Y=N-CH2CH2F, R1=H, R2=OCH3및 R4=H인 화합물.
- 제1항에 있어서, X=N, Y=N-CH2CH2F,R1=H, R2=CH2CH3및 R4=H인 화합물.
- 제1항에 있어서, X=N, Y=NCH2CH2CH2F, R1=H, R2=OCH3및 R4=H인 화합물.
- 제1항에 있어서, X=N, Y=NCH(CH3)2, R1=H, R2=OCH3및 R4=H인 화합물.
- 제1항에 있어서, X=N, Y=NCH2(CH2F)2, R1=H, R2=OCH2및 R4=H인 화합물.
- 제1항에 있어서, X=N, Y=NCH2(CH2F)2, R1=H, R2=CH2CH3및 R4=N인 화합물.
- 제1항에 있어서, X=N, Y=NCH(CH2F)2,R1=H, R2=OCH2CH3및 R4=H인 화합물.
- 하기 일반식을 갖는 화합물을 R1이 수소인 R1-치환된 피페라진 또는 보호된 피페라진으로 처리함을 포함하는, 제1항의 화합물의 제조방법.상기식에서, X, Y, R1, R2및 R3은 상기 정의한 바와 같다.
- 제22항에 있어서, 피페라진을 적어도 1몰 과량으로 사용하는 방법.
- 내인슐린성과 관련된 당뇨병 또는 비만증치료를 필요로 하는 환자에게 유효량의 제1항의 화합물을 투여함을 포함하여, 상기 질병을 치료하는 방법.
- 불활성 담체 및 제1항의 화합물을 포함하는 내일슐린선과 관련된 당뇨병 및 비만증 치료용으로 유용한 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7536287A | 1987-07-20 | 1987-07-20 | |
| US075,362 | 1987-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR890002155A true KR890002155A (ko) | 1989-04-08 |
Family
ID=22125206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019880009044A KR890002155A (ko) | 1987-07-20 | 1988-07-20 | 저혈당제로서의 푸린의 피페라지닐 유도체 및 이의 제조방법 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0300726B1 (ko) |
| JP (1) | JP2562181B2 (ko) |
| KR (1) | KR890002155A (ko) |
| AT (1) | ATE94877T1 (ko) |
| AU (1) | AU601862B2 (ko) |
| CA (1) | CA1341043C (ko) |
| DE (1) | DE3884304T2 (ko) |
| DK (1) | DK403188A (ko) |
| ES (1) | ES2058291T3 (ko) |
| FI (1) | FI883423A (ko) |
| HU (1) | HU199144B (ko) |
| IL (1) | IL87149A (ko) |
| NO (1) | NO167203C (ko) |
| NZ (1) | NZ225447A (ko) |
| PT (1) | PT88029B (ko) |
| YU (1) | YU46761B (ko) |
| ZA (1) | ZA885242B (ko) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL86007A0 (en) * | 1987-04-09 | 1988-09-30 | Wellcome Found | 6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them |
| GB8716313D0 (en) * | 1987-07-10 | 1987-08-19 | Janssen Pharmaceutica Nv | 2-(heterocyclylalkyl)imidazopyridines |
| GB8922076D0 (en) * | 1989-09-28 | 1989-11-15 | Beecham Group Plc | Novel process |
| DK150591D0 (da) * | 1991-08-26 | 1991-08-26 | Novo Nordisk As | Kemisk forbindelse |
| WO1993017021A1 (en) * | 1992-02-19 | 1993-09-02 | Pfizer, Inc. | Heterocyclic compounds for enhancing antitumor activity |
| US5864037A (en) * | 1996-06-06 | 1999-01-26 | Euro-Celtique, S.A. | Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity |
| DE69943144D1 (de) | 1998-03-31 | 2011-03-03 | Kyowa Hakko Kirin Co Ltd | Stickstoffenthaltende heterocyclische verbindungen |
| EP1499598A1 (en) * | 2002-04-18 | 2005-01-26 | Ucb, S.A. | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| EP1568699A4 (en) | 2002-12-04 | 2007-08-15 | Eisai R&D Man Co Ltd | 1,3-DIHYDROIMIDAZOLE CONNECTION WITH CONDENSED RING |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| AU2004269923B2 (en) | 2003-09-05 | 2010-05-13 | Takeda Gmbh | Use of PDE4 inhibitors for the treatment of diabetes mellitus |
| NZ548074A (en) | 2003-12-22 | 2010-08-27 | Gerhard Puerstinger | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment |
| WO2006009736A1 (en) | 2004-06-17 | 2006-01-26 | Wyeth | Processes for preparing gonadotropin releasing hormone receptor antagonists |
| CN101006078A (zh) | 2004-06-17 | 2007-07-25 | 惠氏公司 | 促性腺素释放激素受体拮抗剂 |
| PT1841765E (pt) | 2004-12-21 | 2009-05-14 | Gilead Sciences Inc | Anticorpos para mcp-1 humano |
| US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7538113B2 (en) * | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| CN102600144A (zh) | 2005-03-08 | 2012-07-25 | 奈科明有限责任公司 | 治疗糖尿病的罗氟司特 |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| MX2009000235A (es) | 2006-07-07 | 2009-01-23 | Gilead Sciences Inc | Compuesto de piridazina novedoso y uso del mismo. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| UA99466C2 (en) | 2007-07-06 | 2012-08-27 | Гилиад Сайенсиз, Инк. | Crystalline pyridazine compound |
| EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| CA2730271A1 (en) * | 2008-07-07 | 2010-01-14 | Xcovery Holding Company Llc | Pi3k isoform selective inhibitors |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| UA104010C2 (en) | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
| JP5647998B2 (ja) * | 2009-03-13 | 2015-01-07 | カトリーケ ユニバーシテイト ルーヴェン、ケー．ユー． ルーヴェン アール アンド ディー | 免疫抑制剤としてのチアゾロピリミジン調節因子 |
| AR080711A1 (es) | 2010-03-31 | 2012-05-02 | Lilly Co Eli | Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor |
| BR112012024587A2 (pt) | 2010-03-31 | 2016-05-31 | Lilly Co Eli | compostos de purina usados como agonistas de cb2 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CA3100941C (en) | 2011-03-01 | 2024-03-05 | Synergy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
| JP6499591B2 (ja) | 2013-02-25 | 2019-04-10 | シナジー ファーマシューティカルズ インコーポレイテッド | 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| LT2991987T (lt) * | 2013-05-02 | 2018-08-10 | F. Hoffmann-La Roche Ag | Purino dariniai kaip cb2 receptorių antagonistai |
| US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
| KR102456567B1 (ko) | 2013-08-09 | 2022-10-19 | 알데릭스, 인코포레이티드 | 인산염 수송을 억제하기 위한 화합물 및 방법 |
| CN104497085B (zh) * | 2015-01-16 | 2017-05-24 | 华东理工大学 | 腺苷衍生物及其用途 |
| EP3972599A1 (en) | 2019-05-21 | 2022-03-30 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1115260B (de) * | 1957-02-27 | 1961-10-19 | Thomae Gmbh Dr K | Verfahren zur Herstellung von Purinderivaten |
| GB1186504A (en) * | 1966-10-15 | 1970-04-02 | Fisons Pest Control Ltd | Substituted Heterocyclic Compounds |
| JPS60260579A (ja) * | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | プリン誘導体 |
| JPS6210085A (ja) * | 1985-07-05 | 1987-01-19 | Yoshitomi Pharmaceut Ind Ltd | トリフルオロメチルプリン誘導体 |
-
1988
- 1988-07-18 IL IL8714988A patent/IL87149A/xx unknown
- 1988-07-18 NZ NZ225447A patent/NZ225447A/en unknown
- 1988-07-19 AU AU19230/88A patent/AU601862B2/en not_active Ceased
- 1988-07-19 NO NO883204A patent/NO167203C/no unknown
- 1988-07-19 PT PT88029A patent/PT88029B/pt not_active IP Right Cessation
- 1988-07-19 ES ES88306584T patent/ES2058291T3/es not_active Expired - Lifetime
- 1988-07-19 FI FI883423A patent/FI883423A/fi not_active Application Discontinuation
- 1988-07-19 DE DE88306584T patent/DE3884304T2/de not_active Expired - Fee Related
- 1988-07-19 CA CA000572450A patent/CA1341043C/en not_active Expired - Fee Related
- 1988-07-19 DK DK403188A patent/DK403188A/da not_active Application Discontinuation
- 1988-07-19 EP EP88306584A patent/EP0300726B1/en not_active Expired - Lifetime
- 1988-07-19 HU HU883774A patent/HU199144B/hu not_active IP Right Cessation
- 1988-07-19 AT AT88306584T patent/ATE94877T1/de not_active IP Right Cessation
- 1988-07-20 JP JP63179325A patent/JP2562181B2/ja not_active Expired - Fee Related
- 1988-07-20 ZA ZA885242A patent/ZA885242B/xx unknown
- 1988-07-20 YU YU141088A patent/YU46761B/sh unknown
- 1988-07-20 KR KR1019880009044A patent/KR890002155A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0300726A1 (en) | 1989-01-25 |
| DE3884304D1 (de) | 1993-10-28 |
| HU199144B (en) | 1990-01-29 |
| YU141088A (en) | 1990-10-31 |
| DK403188A (da) | 1989-03-30 |
| PT88029B (pt) | 1995-03-01 |
| JPH01104074A (ja) | 1989-04-21 |
| EP0300726B1 (en) | 1993-09-22 |
| NO883204L (no) | 1989-01-23 |
| ZA885242B (en) | 1989-03-29 |
| JP2562181B2 (ja) | 1996-12-11 |
| FI883423A0 (fi) | 1988-07-19 |
| NO883204D0 (no) | 1988-07-19 |
| IL87149A0 (en) | 1988-12-30 |
| AU601862B2 (en) | 1990-09-20 |
| IL87149A (en) | 1994-05-30 |
| FI883423A (fi) | 1989-01-21 |
| HUT47575A (en) | 1989-03-28 |
| PT88029A (pt) | 1989-06-30 |
| ATE94877T1 (de) | 1993-10-15 |
| NZ225447A (en) | 1991-12-23 |
| ES2058291T3 (es) | 1994-11-01 |
| DK403188D0 (da) | 1988-07-19 |
| AU1923088A (en) | 1989-01-27 |
| YU46761B (sh) | 1994-05-10 |
| CA1341043C (en) | 2000-07-04 |
| NO167203B (no) | 1991-07-08 |
| NO167203C (no) | 1991-10-16 |
| DE3884304T2 (de) | 1994-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR890002155A (ko) | 저혈당제로서의 푸린의 피페라지닐 유도체 및 이의 제조방법 | |
| DE69021472T2 (de) | Pyrazolderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellung. | |
| KR940006590A (ko) | 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물 | |
| CA2311742A1 (en) | 6-amino-9-benzyl-8-hydroxypurine derivatives | |
| IL107426A0 (en) | Heterocyclic compounds, processes for the preparation thereof, and pharmaceutical compositions containing the same | |
| ES2121760T3 (es) | Compuesto de pirazolopiridina y procedimiento para su preparacion. | |
| DE69230163T2 (de) | Thiazolylbenzofuranderivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten | |
| KR920021523A (ko) | 신규한 우레아 유도체, 이의 제조 방법 및 이들을 함유하는 약제학적 조성물 | |
| HUT60250A (en) | Process for producing new phenylimidazolidines, their thione and iminoderivatives, and pharmaceutical compositions comprising same as active ingredient | |
| DE68915225T2 (de) | Benzazol-Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten. | |
| HUT57710A (en) | Process for producing amidine and guanidine derivatives and pharmaceutical compositions comprising such active ingredient | |
| ATE89547T1 (de) | Dopamin-vorlaeufer. | |
| KR910011259A (ko) | 뉴모시스토시스 치료 또는 예방에 사용하기 위한 플루오로퀴놀론 유도체로 구성된 약제 | |
| HUT59124A (en) | Process for producing 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxane derivatives and pharmaceutical compositions comprising such derivatives as active ingredient | |
| HK1044951A1 (en) | Novel a-500359 derivatives | |
| KR890008147A (ko) | 22-데클로로테이코플라닌 | |
| IL103826A0 (en) | Thiazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same | |
| BE881834A (fr) | Medicaments et preparations pharmaceutiques a activite cytostatique | |
| CA2140781A1 (en) | Pharmocologically active .alpha.-¬tertiary-aminomethyl|- benzenemethanol derivatives | |
| HUT56488A (en) | Stabilizer for compositions comprising 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide, stabilizing method and stabilized medicine | |
| DE3675737D1 (de) | Neue kristallmodifikation des 3-methoxy-4-(4'-aminobenzolsufonamido)-1,2,5-thiadiazols, verfahren zu deren herstellung und diese enthaltende pharmazeutische zubereitungen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |